Propanc Biopharma
Update in progressPPCB (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Propanc Biopharma, Inc. is a development-stage biopharmaceutical company focused on cancer therapies for pancreatic, ovarian, and colorectal cancers in Australia. Its lead candidate, PRP, is an intravenous proenzyme treatment that has completed preclinical studies. The company collaborates with the University of Jaén for the POP1 Program and with the University of Granada to develop a synthetic recombinant PRP. It was formerly Propanc Health Group Corporation, renamed in 2017, and was incorporated in 2007 in Camberwell, Australia.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!